STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe…
AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology…
STOCKHOLM, July 1, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2024B, the latest version of…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its…
Enrollment of LGBTQIA+ participants in ambitious population genomics study soars to nearly 40,000 using Vibrent’s digital platformFAIRFAX, Va.--(BUSINESS WIRE)--Vibrent Health,…
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
NASHVILLE, Tenn.--(BUSINESS WIRE)--#aesthetics--ObjectiveHealth, a Nashville-based integrated research and technology platform company, announced today that it is expanding its partnership with…
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s…
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in…
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000…